NEW YORK (GenomeWeb) – Amarantus Bioscience said today that it has reacquired the rights to three neurology diagnostic tests from Avant Diagnostics.

Amarantus has reacquired LymPro Test, MSPrecise, and NuroPro. Under the terms of the deal, Amarantus will cancel all liabilities, totaling about $722,000, owed by Avant. Amarantus will issue to Avant 1 million shares of its common stock, and Avant will issue to Amarantus an additional 32 million shares of its common stock as a repayment of debt.

Amarantus said it plans to assign the diagnostic assets to a new subsidiary.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.